1 2 3 4	Then and NOW: A Prospective Population-Level Validation of the Abbott ID NOW SARS-CoV-2 Device Implemented in Multiple Settings for Testing Asymptomatic and Symptomatic Individuals
5 6 7 8 9 10 11 12 13 14 15	<ul> <li>William Stokes<sup>1,2,3</sup>, MD, Allison A. Venner<sup>1,4</sup>, PhD, Emily Buss<sup>1</sup>, Graham Tipples<sup>1,2,5</sup>, PhD, Byron M. Berenger<sup>1,4</sup>, MD</li> <li><sup>1</sup>Alberta Precision Laboratories, Alberta, Canada</li> <li><sup>2</sup>Department of Pathology and Laboratory Medicine, University of Alberta, Alberta, Canada</li> <li><sup>3</sup>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta</li> <li><sup>4</sup>Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada</li> <li><sup>5</sup>Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada</li> </ul>
16 17	Corresponding author: William Stokes, William.Stokes@AlbertaPrecisionLabs.ca
18	
19	
20	
21	
22	
23	Word count: 3,297
24	
25	
26	
27	
28	
29	
30	

## 31 ABSTRACT

### 32 **IMPORTANCE**

- 33 Since December, 2020, the ID NOW was implemented for use in 4 different populations across
- 34 Alberta: in mobile units as part of community outbreak response, COVID-19 community
- 35 collection sites, emergency shelters and addiction treatment facilities (ES), and hospitals.

## 36 **OBJECTIVE**

- 37 Diagnostic evaluation of the ID NOW in various real world settings among symptomatic and
- 38 asymptomatic individuals

## 39 **DESIGN**

- 40 Depending on the implemented site, the ID NOW was tested on patients with symptoms
- 41 suggestive of COVID-19, asymptomatic close contacts or asymptomatic individuals as part of
- 42 outbreak point prevalence screening. From Jan April, a select number of sites also switched
- 43 from using oropharyngeal swabs to combined oropharyngeal + nasal (O+N) swabs. For every
- 44 individual tested, two swabs were collected: one for ID NOW testing and the other for either
- 45 reverse-transcriptase polymerase chain reaction (RT-PCR) confirmation of negative ID NOW
- 46 results or for variant testing of positive ID NOW results.

## 47 **RESULTS**

- 48 A total of 129,112 paired samples were analyzed (16,061 RT-PCR positive). 81,697 samples
- 49 were from 42 COVID-19 community collection sites, 16,924 from 69 rural hospitals, 1,927 from
- 50 9 ES, 23,802 samples from 6 mobile units that responded to 356 community outbreaks, and
- 51 4,762 from 3 community collection sites and 1 ES using O+N swabs for ID NOW testing. ID
- 52 NOW sensitivity was highest among symptomatic individuals presenting to community
- 53 collection sites [92.5%, 95% confidence interval (CI) 92.0-93.0%, n=10,633 RT-PCR positive]
- and lowest for asymptomatic individuals associated with community outbreaks (73.9%, 95% CI
- 55 69.8-77.7%, n=494 RT-PCR positive). Specificity was greater than 99% in all populations tested,
- 56 but positive predictive value (PPV) was lower among asymptomatic populations (82.4–91.3%)
- 57 compared to symptomatic populations (96.0-96.9%). There was no statistically significant
- 58 differences in sensitivity with respect to age, gender, NP vs OP swab for RT-PCR confirmation,
- 59 variants of concern, or with combined oropharyngeal and nasal swabs using COVID-19 ID
- 60 NOW testing.

## 61 CONCLUSIONS

- 62 Sensitivity of ID NOW SARS-CoV-2 testing is highest when used on symptomatic community
- 63 populations not seeking medical care. Sensitivity and PPV drops by approximately 10% when
- 64 tested on asymptomatic populations. Using combined oropharyngeal and nasal swabs did not
- 65 improve ID NOW performance.
- 66
- 67 Keywords: ID NOW, COVID-19, SARS-CoV-2, POCT, rapid diagnostics, symptomatic,
- 68 asymptomatic
- 69
- 70

#### 71 **INTRODUCTION**

72 The ID NOW (Abbott, Illinois, United States) is approved by the United States Food and Drug 73 Administration (FDA) Emergency Use Authorization for the point of care, rapid detection of 74 severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) in individuals who are within the first 7 days of symptom onset.<sup>1</sup> The ID NOW assay uses isothermal nucleic acid 75 76 amplification of a region of the viral RNA-dependent RNA polymerase (RdRp) to detect the 77 presence of SARS-CoV-2, with results available in under 15 minutes. Clinical specimens 78 approved by U.S. FDA for testing include nasal, oropharyngeal, and nasopharyngeal swabs (NP), 79 which must be tested on the Abbott ID NOW either immediately or within one hour of 80 collection. Specimens placed in viral/universal transport media (UTM) are not valid for testing 81 by the Abbott ID NOW.<sup>1</sup> 82

83 There are many studies that have evaluated the Abbott ID NOW. Its analytical sensitivity 84 approximates 250-500 copies/mL and is significantly higher compared to other lab based RT-PCR platforms, which are typically under 200 copies/mL.<sup>2,3</sup> Pooled clinical sensitivity of the ID 85 86 NOW from 13 studies, compared to RT-PCR, was 73.0% (95% CI 66.8% - 78.4%), and specificity was 99.7% (95% CI 98.7% - 99.4%).<sup>4</sup> However, these studies were limited in sample 87 88 size and heterogeneous in design, such as in differences in specimen type and RT-PCR reference 89 method used. There is also a paucity of data on ID NOW performance in asymptomatic 90 individuals. This is important because ID NOW performance may be negatively affected among 91 asymptomatic individuals with COVID-19, given the higher cycle threshold (Ct) values observed 92 in this population.<sup>5</sup>

94	This study sought to accomplish two goals. The first was to prospectively evaluate the clinical
95	performance of the ID NOW, compared to RT-PCR, after its implementation for SARS-CoV-2
96	testing in various settings across the province of Alberta, Canada (4.4 million people). Based on
97	its rollout, we evaluated the clinical sensitivity and specificity of the ID NOW in these four
98	settings:
99	1) Symptomatic individuals or asymptomatic close contacts presenting to community COVID-19
100	assessment/swab centres.
101	2) Symptomatic inpatients or Emergency Department patients.
102	3) Symptomatic individuals in emergency shelters and addiction treatment facilities.
103	4) Symptomatic or asymptomatic individuals associated with community outbreaks (majority in
104	continuing care centres).
105	
106	The second aim of this study was to compare the differences in sensitivity/specificity between
107	the use of oropharyngeal swabs vs combined oropharyngeal and nasal (O+N) swabs for ID NOW
108	testing in two different COVID-19 testing settings: assessment centres and emergency shelters
109	and addiction treatment facilities. Although oropharyngeal swabs have slightly lower sensitivity
110	compared to nasopharyngeal swab for SARS-CoV-2 detection by RT-PCR, several studies have
111	demonstrated improved sensitivity with O+N swabs. <sup>6-8</sup>
112	
113	METHODS
114	Since December 4, 2020, the ID NOW was gradually implemented across Alberta in the

115 following sites:

116	1) 42 COVID-19 Alberta Health Services (AHS) Public Health assessment/swabbing centres,
117	located in all regions of Alberta: testing of symptomatic individuals and asymptomatic close
118	contacts. These are the primary locations for community patients not needing medical attention
119	to get tested for COVID-19 in Alberta. Testing and swabbing was performed by assessment
120	centre staff (e.g. nurses) within Alberta Precision Laboratories (APL) approved Point of Care
121	Testing (POCT) programs.
122	2) 69 rural hospitals located across Alberta: testing of symptomatic inpatients or ED patients.
123	Swabbing was performed by physicians, nurses, or respiratory therapists. Testing was performed
124	in a College of Physician and Surgeons of Alberta (CPSA) accredited hospital laboratory (APL).
125	3) 9 emergency/homeless shelters and addiction treatment facilities, located in urban centres in
126	Alberta: testing of symptomatic residents. Testing and swabbing performed on site by registered
127	nurses.
128	4) 6 mobile units that accessed all regions of Alberta: testing of symptomatic or asymptomatic
129	residents or staff, all from organizations on outbreak (majority were continuing care sites).
130	Swabbing and testing performed by mobile nursing team staff on-site in retrofitted vans.
131	
132	Individuals were given the option to have POCT by ID NOW and routine testing, or routine
122	
133	testing alone. All individuals tested with the ID NOW had two parallel swabs collected. The first
133	testing alone. All individuals tested with the ID NOW had two parallel swabs collected. The first swab collected was either a NP swab or oropharyngeal (OP) swab, which was placed in UTM
134	swab collected was either a NP swab or oropharyngeal (OP) swab, which was placed in UTM
134 135	swab collected was either a NP swab or oropharyngeal (OP) swab, which was placed in UTM (Yocon Biology, Beijing, China or GDL Korea Co. Ltd, Seoul, Korea) for RT-PCR, and

139	individuals had a sample available for RT-PCR (i.e. in case the individual refused the second NP
140	or OP swab). If the ID NOW test was negative, the second swab was sent for confirmatory RT-
141	PCR testing. If the ID NOW test was positive, the second swab was either sent for storage (if
142	collected before February 1, 2021) or for variant of concern screening (VoC) testing. Samples
143	sent for storage (-70°C) were tested at a later date for SARS-CoV-2 using RT-PCR. All RT-PCR
144	tests sent for variant testing were done within approximately 72 hours from time of collection.
145	
146	All RT-PCR testing was performed on the APL Public Health Laboratory E gene PCR or on a
147	Health Canada and FDA approved commercial assay. <sup>9</sup> Commercial assays were dependent on
148	the testing lab and included the Allplex (Seegene, Seoul, South Korea), BDMax (Becton
149	Dickinson, NJ, United States), Panther (Hologic, MA, United States), GeneXpert SARS-CoV-2
150	or SARS-CoV-2/Influenza/RSV (Cepheid, CA, United States), Cobas 6800 System (Roche
151	Molecular Systems, CA, United States) and Simplexa (DiaSorin, Saluggia, Italy). All samples
152	sent for VoC screening were tested with the ProvLab E gene assay to determine if sufficient viral
153	load was present for VoC testing. E gene RT-PCR results from our lab-developed test were
154	considered positive for SARS-CoV-2 when E gene cycle threshold (Ct) value was <35.
155	If the Ct was $\geq$ 35, amplification from the same eluate was repeated in duplicate and was
156	considered positive if at least $2/3$ results had a Ct $<41$ .
157	
158	All personnel performing the ID NOW swabbing/testing were trained healthcare workers
159	(HCW), who were previously trained in NP and oropharyngeal swab collection. At time of

160 collection, they asked and recorded whether the patient had symptoms or was asymptomatic. All

161 sites and HCW were trained on the ID NOW collection, transport, and testing processes, at least

162	according to the manufacturer's instructions, prior to ID NOW implementation. AHS staff were
163	trained according to the APL POCT program, which meets CPSA accreditation standards. Each
164	ID NOW device underwent a verification process, which included testing 3 positive ID NOW
165	control swabs and 5 negative ID NOW control swabs on the ID NOW instrument before use.
166	One positive control and one negative control swab were tested on the ID NOW instrument after
167	each new box of ID NOW kits was opened, after each new HCW was trained on the instrument,
168	and, after each instrument was transported to a different site.
169	
170	All ID NOW samples with parallel RT-PCR results documented were included in our study.
171	Results without proper documentation of testing location, or without either confirmatory RT-
172	PCR or variant testing were excluded.
173	
174	Between Jan 26 and April 12, 2021, 3 assessment centres and one shelter and addiction treatment
175	facility switched from using oropharyngeal swabs to O+N swabs for ID NOW testing. The swab
176	used remained the same (swab provided in Abbott ID NOW kits) and instructions for swabbing
177	was provided to individual sites (see supplementary material for instruction details). All other
178	protocols, as outlined above, remained in place.
179	
180	Data was pulled from our provincial laboratory's centralized electronic database containing
181	SARS-CoV-2 results for all publicly funded testing in the province except for border testing.
182	Sensitivity and specificity of the ID NOW was calculated with Clopper-Pearson 95% confidence
183	intervals. Statistical analysis was performed using Pearson Chi-squared for categorical variables

and t-test for continuous variables using STATA (version 14.1).

185 The University of Alberta Research Ethics board approved this study (Pro00111835).

186

#### 187 **RESULTS**

- 188 A total of 133,919 results were identified between December 4, 2020 and November 24, 2021.
- 189 4807 samples were excluded: 190 did not have testing location recorded, 375 did not have an ID
- 190 NOW result recorded, 3 had invalid ID NOW results, 2,417 ID NOW results did not have
- 191 parallel RT-PCR results recorded, and 1,822 positive ID NOW results did not have subsequent
- 192 variant testing performed. The remaining 129,112 paired samples were analyzed.
- 193
- 194 ID NOW testing using oropharyngeal swabs

195 124,350 samples (15,649 RT-PCR positive) were analyzed. 81,697 samples were from 42

assessment centres, 16,924 samples were collected from 69 rural hospitals, 1,927 samples were

197 from 9 shelters and addiction treatment facilities, and 23,802 samples were from 6 mobile units

that responded to 356 outbreaks. Baseline characteristics of these samples is provided in Table 1.

199 Results, compared to RT-PCR, are provided in Table 2 and Figure 1. ID NOW sensitivity was

200 highest among symptomatic individuals presenting to assessment centres [92.5%, 95%

201 confidence interval (CI) 92.0-93.0%, n=10,633 RT-PCR positive], and lowest for asymptomatic

- 202 individuals associated with community outbreaks (73.9%, 95% CI 69.8-77.7%, n=494 RT-PCR
- 203 positive). There was an approximate 10% decrease in sensitivity when testing asymptomatic vs
- symptomatic populations. Specificity was greater than 99% in all populations tested.

- 206 Positive predictive value (PPV) was highest for symptomatic individuals presenting to
- assessment centres (PPV 96.9%, 95% CI 96.5-97.2%), followed by symptomatic patients in

208	hospital or emergency rooms (96.4%, 95% CI 95.7-97.1%), symptomatic patients tested via
209	mobile units (96.0%, 94.1-97.3%), asymptomatic individuals presenting to assessment centres
210	(91.3%, 95% CI 89.2-93.1%), symptomatic individuals at emergency shelters and addiction
211	treatment facilities (88.6%, 95% CI 79.3-94.0%) and asymptomatic patients tested via mobile
212	units (82.4%, 95% CI 78.8-85.5%). Negative predictive value (NPV) was highest for
213	asymptomatic patients tested via mobile units (99.3%, 95% CI 98.8-99.1%), symptomatic
214	individuals at emergency centres and addiction treatment facilities (99.0%, 95% CI 98.5-99.3%),
215	symptomatic individuals presenting to assessment centres (98.7%, 95% CI 98.6-98.8%),
216	asymptomatic individuals presenting to assessment centres (98.6%, 95% CI 98.3-98.8%),
217	symptomatic patients tested via mobile units (98.0%, 95% CI 97.6-98.4%), and symptomatic
218	patients in hospital or emergency rooms (97.8%, 95% CI 97.6-98.0%).
219	
220	Ct values for ID NOW true positive and true negative results is provided in Table 3. Mean E
221	gene Ct values were significantly higher among ID NOW false negatives compared to true
222	positives and among asymptomatic compared to symptomatic populations, with the exception of
223	mean E gene Ct value of false negatives between symptomatic vs asymptomatic in mobile testing
224	and in assessment centres using O+N swabs (p>0.05).
225	
226	There was no significant difference in sensitivity and specificity of ID NOW when comparing
227	symptomatic and asymptomatic patients under 5 years of age, under 10 years of age, under 18
228	years of age, and over 18 years of age (Supplementary Table 1-4). There was no significant

229 difference in sensitivity and specificity of ID NOW when comparing symptomatic and

asymptomatic patients based on gender (Supplementary Table 5-6).

23	1

231	
232	There was no significant difference in sensitivity when a NP or OP swab for confirmatory RT-
233	PCR (or variant) testing was done among symptomatic or asymptomatic patients (Supplementary
234	Table 7-8). However, there was slight differences in specificity, with OP swabs having higher
235	specificity compared to NP swabs. There was no significant difference in sensitivity between
236	symptomatic or asymptomatic patients with alpha compared to the delta variant (Supplementary
237	Table 9-10).
238	
239	ID NOW testing using combined oropharyngeal and nasal swabs
240	4,762 paired samples were analyzed (412 RT-PCR positive). 4,571 samples were from 3
241	assessment centres and 191 samples were collected from 1 urban emergency shelter. Baseline
242	characteristics of these samples is provided in Table 1. ID NOW results, compared to RT-PCR,
243	are provided in Table 2. There was no statistically significant differences in sensitivity or
244	specificity noted between results from ID NOW using oropharyngeal swabs and those using
245	O+N swabs (Figure 2).
246 247	
248	DISCUSSION
249	Use of point of care SARS-CoV-2 tests, such as the ID NOW, for the detection of SARS-CoV-2
250	among individuals remains a worthwhile endeavour. Even if confirmatory testing of negatives is
251	performed, identifying positives at the point of care has several advantages. It can speed

252 important public health measures, such as contact tracing and isolation. Moreover, it has

significant benefits for the laboratory in terms of decreasing contamination error and improving

254 laboratory processes. For instance, decreasing the number of positive samples entering the

laboratory can decrease the risk of false positive results by reducing the probability of SARSCoV-2 contamination during RT-PCR testing. In addition, the decrease in positive samples can
improve efficiencies in other laboratory processes, such as pooling.

258

259 In our large, multicentre, population-based study, we observed differing ID NOW sensitivities, 260 compared to RT-PCR, based on the population being tested. Sensitivity was highest (92.5%) 261 when tested among symptomatic individuals presenting to community COVID-19 assessment 262 centres and lowest for asymptomatic individuals associated with community outbreaks (73.9%, 263 95% CI 69.8-77.7%, n=494 RT-PCR positive). These results highlight that the ID NOW 264 performance is not standard across populations tested, likely as a result of its poorer performance 265 with lower viral loads, as can be observed among asymptomatic individuals or individuals who are further out from their symptom onset.<sup>5</sup> This outcome can better help direct where ID NOW 266 267 devices are most suitable, and provide information to consider when goals of testing are 268 reviewed. As expected, we observed lower average E gene Ct values among symptomatic 269 individuals compared to asymptomatic individuals and among ID NOW false negative compared 270 to true positive samples. Higher Ct values observed in results from emergency shelters and 271 addiction treatment facilities is likely a manifestation of the unique population being tested. 272 While testing was limited to individuals with symptom onset within the first 7 days, it can be 273 challenging to differentiate those with symptoms in these settings, particularly those who spend 274 frequent time outside in the cold (i.e. rhinorrhea), and have fluctuating symptoms related to other 275 factors such as drug use.

276

277 ID NOW sensitivity was slightly lower in the symptomatic populations tested using a mobile 278 service or in-hospital based settings. There may be various factors to account for this. Firstly, ID 279 NOW testing is performed immediately after sample collection at assessment centres, whereas 280 hospitals and mobile service often require transportation to the on-site lab or mobile unit prior to 281 ID NOW testing. While ID NOW testing was mandated to be done within 1 hour from collection, short periods of time from transportation may potentially affect performance.<sup>10</sup> 282 283 Secondly, a higher proportion of individuals with lower viral loads may be tested in hospitals and 284 via mobile. For mobile testing (mostly outbreaks), individuals with symptoms were possibly 285 early in their symptom onset at time of testing, whereas those presenting to hospitals were 286 possibly late in their symptom onset; both of which can be associated with higher Ct values and, therefore, lower viral loads.<sup>5</sup> Symptomatic individuals presenting to assessment centres, in 287 288 comparison, are often within the first few days of symptom onset, but because it generally takes 289 approximately 24 hours to arrange a booking, are not at the very beginning of their symptom 290 onset.

291

There are clear differences in ID NOW sensitivity with respect to symptoms, with asymptomatic populations having an approximately 10% decrease in sensitivity. There were significantly higher mean E gene Ct values observed when testing asymptomatic versus symptomatic individuals in assessment centres. This has important implications when using the ID NOW for screening of asymptomatic populations, where the implications of a rapid test for such a population needs to be carefully considered and weighed over the risks of a substantial decrease in sensitivity compared to other testing methods (RT-PCR). However, the sensitivity of the ID

299	NOW compared to other point of care options, including rapid antigen tests, is far superior, with
300	the sensitivity of rapid antigen tests ranging from 30-50% in asymptomatic populations. <sup>4</sup>
301	

ID NOW sensitivity in our study is underestimated due to the large number (1,822, 11.3% of
positives) of ID NOW positives that were excluded from our analysis, 93% of which came from
symptomatic individuals from assessment centres. These were excluded due to the lack of
parallel RT-PCR testing. If these excluded samples were included as true positives, sensitivity of
symptomatic individuals presenting to assessment centres would increase to 93.5% (95% CI
93.0-93.9%).

308

309 ID NOW specificity was consistently high across the populations tested (>99%), and is consistent with prior studies within the literature.<sup>4</sup> When comparing ID NOW to RT-PCR from 310 311 individuals with confirmed COVID-19, we previously demonstrated a significant number of ID NOW positive, RT-PCR negative discrepant results.<sup>10</sup> This suggests that other factors may 312 313 account for discrepant results, such as sampling error. It is noted that multiple individuals within 314 our dataset had an ID NOW positive result followed by subsequent negative RT-PCR, but then 315 on repeat RT-PCR the next day were positive. These patients were considered ID NOW false 316 positives in our study, although in reality would be considered true positives based on this 317 information. As such, ID NOW specificity is likely higher than what we have reported. Although 318 the exclusion of many ID NOW positive results in our study may contribute to overestimation of 319 ID NOW specificity, this would be primarily limited to symptomatic individuals at assessment 320 centres, and would have little to no impact on the specificity observed among other populations 321 studied.

322

323	Using an oropharyngeal swab or O+N swab for ID NOW testing yielded similar results among
324	both symptomatic and asymptomatic populations. Given the higher inconvenience with O+N
325	swabs, and the lack of advantages demonstrated over typical specimens, we recommend against
326	using O+N swabs for ID NOW COVID-19 testing.
327	
328	Strengths of this study include the large sample size and including both symptomatic and
329	asymptomatic populations. We also studied testing in various real world locations, including
330	community COVID-19 assessment centres, hospitals (inpatient and ED), emergency shelters and
331	addiction treatment facilities, and continuing care and industry outbreaks. Due to the introduction
332	of mandatory testing of many positive ID NOW or RT-PCR samples for variants of concern,
333	which included E gene RT-PCR from a consistent RT-PCR testing platform (APL LDT), we
334	were able to assess the specificity of the ID NOW and examine the relationship of E gene Ct
335	values between true positive and false negative ID NOW results.
336	
337	Our study had several limitations. Due to the heterogeneity of our populations tested, it is
338	difficult to exclude confounders that may have contributed to ID NOW performance. However,
339	no differences were observed in sensitivity based on common patient, collecting and testing
340	characteristics, including age, gender, swab used, and variants of concern detected. Specificity
341	was increased for RT-PCR samples collected using oropharyngeal swabs, but this difference was
342	slight and limited to symptomatic populations. Exclusion of some ID NOW positive results from
343	our study because of no parallel RT-PCR testing did have an impact on ID NOW performance,
344	as evidenced by improved sensitivity (93.5% vs 92.5%), among symptomatic community

345	patients presenting to assessment centres, when including these positive samples. Reasons
346	behind missing parallel RT-PCR are multifactorial and include sample lost or discarded prior to
347	testing, testing sites going against guidelines and not obtaining a second swab for RT-PCR
348	confirmation, and patient demographic mismatches resulting in test cancellation or inability to
349	match ID NOW and RT-PCR tests together in our electronic database. These excluded samples,
350	however, would have little impact on ID NOW sensitivity and specificity outside of symptomatic
351	individuals presenting to assessment centres. For instance, no significant changes in sensitivity
352	among asymptomatic community patients that presented to assessment centres were observed
353	when the 1822 excluded positive results were subsequently analyzed.
354	
355	In conclusion, the performance of the ID NOW differs across populations tested for SARS-CoV-
356	2. ID NOW performance can be maximized if testing is limited to symptomatic individuals
357	presenting to community testing sites (assessment centres). Sensitivity drops by approximately
358	10% when the testing population is asymptomatic. ID NOW performance is not affected by age,
359	gender, or variants of concern (alpha, delta). ID NOW testing with combined oropharyngeal +
360	nasal swab had no effect on performance.
361	
362	
363	Acknowledgments
364	This work was funded using internal operating funds of Alberta Precision Laboratories and
365	Alberta Health Services. Test kits and instruments were paid for by the Public Health Agency of

366 Canada. We thank staff at AHS assessment centre, mobile teams, and staff at shelters and

367 addiction recovery sites for collecting and testing samples in the community, and Alberta

- 368 Precision Laboratory staff for assistance with testing of samples, and in the development and
- 369 support of the various testing programs.
- 370
- 371
- 372 **Declarations**
- 373 Funding: Internal funding from Alberta Precision Laboratories.
- 374 *Conflict of Interest:* The manufacturer had no role to play in the study. The authors have no
- 375 conflict of interests to disclose pertaining to this study.
- 376 Availability of data: Available upon request.
- 377

## 378

#### 379 **REFERENCES**

- United States Food and Drug Administration. ID NOW COVID-19 instructions for use.
   2020. [Accessed Feb 10, 2022]. Available from:
- 382 <u>https://www.fda.gov/media/136525/download</u>
- Fung B, Gopez A, Servellita V, Arevalo S, Ho C, Deucher A, Thornborrow E, Chiu C,
   Miller S. Direct comparison of SARS-CoV-2 analytical limits of detection across seven
   molecular assays. *J Clin Microbiol*. 2020 Aug 24;58(9):e01535-20.
- 386
   3. Lephart PR, Bachman MA, LeBar W, et al. Comparative study of four SARS-CoV-2
   387
   388
   388
   389
   389
   380
   380
   380
   380
   381
   381
   382
   383
   384
   385
   385
   386
   386
   387
   388
   389
   380
   380
   380
   380
   380
   380
   380
   380
   381
   382
   383
   384
   385
   385
   386
   386
   387
   387
   388
   388
   389
   389
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   380
   38
- 390
  4. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based
  391
  392
  392
  2021;3:CD013705.
- Stokes W, Kanji JN, Hu J, Zelyas N, Berenger BM. Wide variation in threshold cycle
   values clouds the interpretation of SARS-CoV-2 infectiousness. *Clin Chem.* 2021;68(1):253-255.
- 396
  397
  398
  6. Vlek ALM, Wesselius TS, Achterberg R, Thijsen SFT. Combined throat/nasal swab sampling for SARS-CoV-2 is equivalent to nasopharyngeal sampling. *Eur J Clin Microbiol Infect Dis*. 2021;40(1):193-195.
- 399
  7. Desmet T, Paepe P, Boelens J, et al. Combined oropharyngeal/nasal swab is equivalent to 400 nasopharyngeal sampling for SARS-CoV-2 diagnostic PCR. *BMC Microbiol*.
  401 2021;22;21(1):31. PMID: 33482729.
- 402 8. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. Performance of saliva,
  403 oropharyngeal swabs, and nasal swabs for SARS-CoV-2 molecular detection: a
  404 systematic review and meta-analysis. *J Clin Microbiol*. 2021;59(5):e02881-20.

- Pabbaraju, et al. Development and validation of reverse transcriptase-PCR assays for the testing of SARS-CoV-2. *JAMMI*. 2020. Doi:10.3138/jammi-2020-0026: e20200026
- 407 10. Stokes W, Berenger BM, Singh T, et al. Acceptable performance of the Abbott ID NOW
  408 among symptomatic individuals with confirmed COVID-19. *J Med Microbiol*.
  409 2021;70(7):001372. PMID: 34309503.

- 412 Table 1: Characteristics between individuals tested with ID NOW SARS-CoV-2 using
- 413 oropharyngeal swabs or combined oropharyngeal and nasal (O+N) swabs.

Site	Symptoms	Mean age (median, range)	Male gender (%)	NP swab used for parallel RT-PCR testing <sup>*</sup> (%)
	OROPHARYNGEA	L SWAB FOR ID	NOW T	
Assessment	Symptomatic (n=70,879)	34.7 (34.4, 0.04-101)	40.5%	49.9%
centre	Asymptomatic** (n=10,818)	34.5 (32.4, 0.1- 102)	46.8%	40.7%
Hospital	Symptomatic (n=16,924)	50.7 (53.6,0.0007- 107.9)	48.0%	90.2%
emergency shelters and addiction treatment facilities	Symptomatic (n=1,927)	42.2 (39.2, 2.7- 101.2)	60.8%	14.2%
Mobile unit	Symptomatic (n=4,224)	31.8 (31.1, 0.001-103.9)	38.9%	15.5%
	Asymptomatic (n=19,578)	51.4 (47.8,0.5- 107.2)	43.5%	56.0%
COMBINED	OROPHARYNGEA	L AND NASAL S	WAB FO	R ID NOW TESTING
Assessment	Symptomatic (n=3890)	35.6 (35.9, 0.7- 98.3)	40.8%	68.7%
centre	Asymptomatic** (n=681)	31.2 (29.1,3.4- 83.1)	48.6%	76.8%
emergency shelters and addiction treatment facilities	Symptomatic (n=191)	40.6 (39.4,19.1- 68.2)	62.8%	1.1%

8 \*\*Asymptomatic close contacts only

<sup>\*</sup>Either NP or oropharyngeal swab was used for parallel RT-PCR testing. In hospitalized patients, a minority of samples were other specimen types such as endotracheal tube aspirates.


- 428 Table 2: Performance of ID NOW, compared to RT-PCR, using oropharyngeal swabs or
- 429 combined oropharyngeal and nasal (O+N) swabs.

	Oropharyngeal Swab				O+N Swab					
Asses	Assessment Centre: Symptomatic				Assessment Centre: Symptomatic					
		RT-PCR					RT	-PCR		
		Positive	Negative				Positive	Negative		
ID	Positive	9833	315		ID	Positive	335	18		
NOW	Negative	800	59,931		NOW	Negative	28	3,509		
Assess	Assessment Centre: Asymptomatic					Assessment Centre: Asymptomatic				
		RT-PCR					RT-PCR			
		Positive	Negative				Positive	Negative		
ID	Positive	768	73		ID	Positive	35	5		
NOW	Negative	140	9,837		NOW	Negative	10	631		
<b>Emergency Shelters and Addiction</b>					<b>Emergency Shelters and Addiction</b>					
<b>Treatment Facilities</b>				Treatment Facilities						
			PCR					-PCR		
		Positive	Negative				Positive	Negative		
ID	Positive	62	8		ID	Positive	3	0		
NOW	Negative	19	1838		NOW	Negative	1	187		
Hospital										
		RT-PCR								
		Positive	Negative							
ID	Positive	2,624	97							
NOW	Negative	308	13,895							
Mobile: Symptomatic										
			PCR							
		Positive	Negative							
ID	Positive	529	22							
NOW	Negative	72	3,601							
	Mobile: Asymptomatic									
		RT-PCR								
		Positive	Negative							
ID	Positive	365	78	ļ						
NOW	Negative	129	19,006							

440 Figure 1: Sensitivity and specificity of ID NOW (oropharyngeal swab) compared to RT-PCR

441 (oropharyngeal swab or nasopharyngeal swab). Error bars represent 95% confidence intervals.

- AC = assessment centre.







# 464

465

466

# Table 3: Cycle threshold of ID NOW true positives (ID NOW +, RT-PCR +) and false negatives (ID NOW -, RT-PCR +) between sites and populations tested.

Site	Symptomatic	Variant (%)	Mean E gene Ct of	Mean E gene Ct of				
	VS		true positives	false negatives				
	Asymptomatic		(median, range)	(median, range)				
OROPHARYNGEAL SWAB								
	Symptomatic	Wild-type (13.3%)	23.4 (22.6, 13.8-41.0)	29.7 (31.6, 14.7-41.0)				
		Delta (41.1%)						
		Alpha (33.6%)						
		Unresolved (8.0%)						
Assessment centre		Other** (2.0%)						
	Asymptomatic <sup>*</sup>	Wild-type (18.9%)	26.2 (26.2, 13.9-38.4)	31.8 (33.2, 18.5-40.7)				
		Delta (17.6%)						
		Alpha (43.5%)						
		Unresolved (19.0%)						
		Other** (1.1%)						
Emergency shelters	Symptomatic	Wild-type (35.6%)	25.9 (26.2, 15.0-35.7)	36.3 (36.3, 34.5-38.1)				
and addiction		Delta (35.6%)						
treatment facilities		Alpha (10.2%)						
		Unresolved (16.9%)						
		Other** (0.5%)						
	Symptomatic	Wild-type (3.7%)	22.8 (22.0,13.7-41.0)	30.2 (31.6, 15.5-39.9)				
Hospital		Delta (72.2%)						
		Alpha (12.8%)						
		Unresolved (10.1%)						
		Other** (1.1%)						
	Symptomatic	Wild-type (10.8%)	25.3 (24.9, 14.7-37.7)	33.0 (34.3, 18.8-38.1) <sup>#</sup>				
		Delta (49.4%)						
		Alpha (25.9%)						
Mobile		Unresolved (12.7%)						
		Other** (1.1%)						
	Asymptomatic	Wild-type (17.6%)	26.7 (27.0, 14.9-40)	33.9 (34.9,18.2-41.0) #				
		Delta (20.3%)						
		Alpha (26.5%)						
		Unresolved (32.7%)						
		Other** (2.9%)						
			ND NASAL (O+N) SWA					
	Symptomatic	Wild-type (59.3%)	22.6 (21.6,14.0-38.6)	28.4 (32.4,15.3-38.1)#				
		Alpha (28.4%)						
Assessment centre		Unresolved (12.1%)						
	Asymptomatic*	Wild-type (32.7%)	25.1 (25.2,15.3-38.1)	30.4 (28.3,26.2-36.7) <sup>#</sup>				
		Alpha (32.7%)						
		Unresolved (34.7%)						

\*Asymptomatic close contacts only

\*\*Beta, Gamma, non-variant of concern, Unknown)

 $^{\#}P<0.01$  for all comparisons of mean E gene Ct of true positives vs false negatives and symptomatic vs asymptomatic within each group, with the exception of false negatives between symptomatic vs asymptomatic in mobile testing and in assessment centres using O+N swabs (p>0.05).

 $\begin{array}{r} 469\\ 470\\ 471\\ 472\\ 473\\ 474\\ 475\\ 476\\ 477\\ 478\end{array}$ 



Figure 2: Sensitivity and specificity of ID NOW, compared to RT-PCR, for ID NOW specimens
collected using either oropharyngeal swab or combined oropharyngeal and nasal (O+N) swab at
COVID-19 assessment centres. Error bars represent 95% confidence intervals.

